Kore.ai Launches Artemis, the New Generation of the Kore.ai Agent Platform for Building, Governing, and Optimizing Enterprise AI 
Smilepayz Expands Global Payment Network Through Strategic Payment Orchestrator Collaborations in 2026 Idaho Champion Completes 2021 IP Survey, Outlining Significant Anomaly Covering Nearly 8 Square Kilometers at Champagne Gold Project
TORONTO, ON / ACCESSWIRE / December 6, 2021 / Idaho Champion Gold Mines Canada Inc….
Talisker Announces Royalty Purchase Agreement with Osisko Gold Royalties
TORONTO, ON / ACCESSWIRE / December 6, 2021 / Talisker Resources Ltd. (“Talisker” or the…
Tin Cup Drilling Update
VANCOUVER, BC / ACCESSWIRE / December 6, 2021 / Northern Lights Resources Corp. (“Northern Lights”…
ORhub Announces Sean McMenamin as An Independent Member of The Board
IRVINE, CA / ACCESSWIRE / December 6, 2021 / ORHub, Inc. (OTC PINK:ORHB) ORHub today…
SUIC New York Office Announces A Solid Launch Lineup Of Its Starry Marketing Master Model That Will Bring Two Ecosystems, Midas Touch Lending-Borrowing and Beneway New Age Bank, To The 50 States In The U.S.
NEW YORK, NY and TAIPEI, TAIWAN / ACCESSWIRE / December 6, 2021 / Sino United…
Promising Cardano-based DEX Joins the Race: Do.Exchange (DOEX) to hold a Public sale on KICK.IO
TALLINN, ESTONIA / ACCESSWIRE / December 6, 2021 / Cardano is the blockchain of the…
XPhyto Completes Strategic Acquisition of 3a-diagnostics GmbH
The acquisition positions XPhyto to be a leading Biosensor producer integrating thin film technology with…
Appointment of Nigel Little as Non-Executive Director
LONDON, UK and CALGARY, AB / ACCESSWIRE / December 6, 2021 / Canadian Overseas Petroleum…
Arkady Volozh Extends Lock-up for an Additional Two Years
MOSCOW, RUSSIA and AMSTERDAM, the NETHERLANDS / ACCESSWIRE / December 6, 2021 / Yandex (NASDAQ…
Tumorad(R) Shows Good Safety in Preclinical Studies
LUND, SWEDEN / ACCESSWIRE / December 6, 2021 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F) Spago Nanomedical…
From now on, msg life and msg nexinsure will share the new co-brand msg insur:it
(Leinfelden-Echterdingen/Ismaning, 6 December 2021) – msg life ag and msg nexinsure ag have been working…
Valneva SE: declaration of shares and voting rights – November 2021
VALNEVA Declaration of shares and voting rights November 30, 2021 __________________________________________________________________________________________ Company name: VALNEVARegistered office:…
OKYO Pharma Limited (“OKYO” or the “Company”) to File IND in Q3 2022 for OK-101 to treat Dry Eye Disease (“DED”) and to go directly to a Phase 2 Human Clinical Efficacy Trial in DED Patients with a planned start date in Q4 2022 on an accelerated basis
LONDON, Dec. 06, 2021 (GLOBE NEWSWIRE) — OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), the…
Bavarian Nordic Commits to Initiating Phase 3 Trial of RSV Vaccine Candidate and to Strengthening its Capital Base
Bavarian Nordic to initiate Phase 3 with RSV vaccine candidate in first half of 2022…
Roche to launch SARS-CoV-2 & Flu A/B Rapid Antigen Test in countries accepting the CE Mark to enable rapid differentiation of viral respiratory infections
The combination rapid antigen test quickly differentiates between SARS-CoV-2 and influenza viruses A and B…
Santhera to Host Investor Conference Call — Looking Ahead to 2022
Pratteln, Switzerland, December 6, 2021 – Santhera Pharmaceuticals (SIX: SANN) is pleased to invite investors, shareholders,…
Sequana Medical Announces the Completion of Patient Enrolment in POSEIDON, the North American Pivotal alfapump® Study
Positive interim analysis reported in July 2021 Reporting of primary endpoint planned for Q4 2022…
HUTCHMED Completes Planned Enrollment of FRESCO-2, a Global Phase III Trial of Fruquintinib in Metastatic Colorectal Cancer
— Recruitment of 687 patients globally completed in fifteen months, ahead of schedule — — FRESCO-2 primary…
Rexlemestrocel-L Shows Greatest Treatment Benefit on Major Adverse Cardiovascular Events in High-Risk Heart Failure Patients With Diabetes and/or Myocardial Ischemia
Endpoint in Line with FDA Guidance on Key Outcomes in High-Risk Patients and with Pharma…
Junshi Biosciences Announces FDA Expanded Emergency Use Authorization for Etesevimab and Bamlanivimab Administered Together to Include Individuals under the Age of 12
First and only neutralizing antibody therapy for this age group SHANGHAI, China, Dec. 06, 2021…